Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life
Authors' conclusion
RR-DTC with good performance status and RAI-avid disease obtains the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.
Study context
- Population
- Radioiodine-refractory DTC (radioiodine-refractory differentiated thyroid cancer (RR-DTC)) treated with lenvatinib in real life, 3 Italian thyroid cancer referral centres
- Participants
- 55 participants
- Outcome
- PFS and OS
Methodological detailsmulticentre, Lenvatinib was first-line kinase inhibitor in 96.4% of subjects
- Multicentre
- Lenvatinib was first-line kinase inhibitor in 96.4% of subjects
Main finding
As reported in the abstract
Median progression-free survival (PFS)
26 months
95% CI 19.06–32.93
Median overall survival (OS)
70 months
95% CI 36–111.99
Observational data: associations, not effects.
Further findings
Pretreatment predictors: Eastern Cooperative Oncology Group (ECOG) performance status (score 0-1 as reference)
- PFS: HR 18.82; 95% CI 3.65-97.08; P < .001
- OS: HR 6.20; 95% CI 2.11-18.20; P = .001
- Independently related
Pretreatment predictor: Radioactive iodine (RAI) avidity (avid disease as reference)
- PFS: HR 3.74; 95% CI 1.01-13.76; P = .047
- Independently related
ECOG 0-1 and RAI-avid disease · median follow-up 81 months
- Objective response
- 100%
- Median PFS
- 45 months
- Deaths
- 0
Posttreatment predictor: best radiological response (partial/complete response as reference)
- PFS: HR 4.6; 95% CI 1.89-11.18; P = .001
- OS: HR 2.94; 95% CI 1.25-6.89; P = .013
- Independently predicted
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →